First Author: S.Koshy UK
Co Author(s): E. Vrizidou H. Eleftheriadis 0 0 0 0 0 0 0 0 0
Back to previous
To study the six months results of ranibizumab 0.5 mg monotherapy based on mean average change in vision in diabetic macular oedema.
King’s College Hospital, Department of Ophthalmology, Normanby Building, Denmark Hill, London, SE5 9RS, UK
The medical records of patients treated with intravitreal injections of ranibizumab for diabetic macular oedema were studied retrospectively. Ranibizumab was given for 3 months then pro re nata (PRN). The main outcome measure was the mean average change in recorded vision from baseline to month 1 through to month 6. Secondary outcome measures were the mean change in central subfield retinal thickness and mean change in macular volume.
Thirty nine eyes of 34 patients (13 females) 62±9.5 years of age were studied. Ranibizumab resulted in a +5.9 EDTRS letters average change in vision at 6 months. Best vision at 6 months was significantly better than at baseline (63.7 vs 59, p=0.0031) after an average number of 5.3 injections. At 6 months the vision improved in 69% of the eyes compared to baseline, with 44% of the eyes improving by at least 1 EDTRS line and 23% by at least three lines. The central subfield thickness at 6 months was reduced by 138 μm from 496 μm at baseline (p<0.0001) and the macular volume was reduced by -1.65 mm3 from 10.79 mm3 (p<0.0001). None of the patients experienced any serious adverse events attributed to ranibizumab.
Treatment of diabetic macular oedema with intravitreal injections of ranibizumab, using a regimen of three loading injections followed by monthly PRN, achieves very satisfactory 6 months results, in a UK National Health Service hospital setting.